Cancer Treatment Methods Targeting Biallelic Loss of Function Mutations
Summary
European Patent Office published application EP4330426A1 for Repare Therapeutics Inc., covering methods of treating cancers having biallelic loss of function or gene overexpression mutations. The patent application includes chemical compound classifications under A61K, C07D, C12Q, and A61P categories, with a publication date of April 15, 2026. Designated states cover all current EPO member states including Germany, France, United Kingdom, Italy, Spain, Netherlands, and 24 other European jurisdictions.
About this source
GovPing monitors EPO Patent Bulletin - Organic Chemistry (C07D) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 63 changes logged to date.
What changed
The European Patent Office published patent application EP4330426A1 for Repare Therapeutics Inc., covering methods of treating cancers having biallelic loss of function or gene overexpression mutations. The application includes claims across multiple IPC classifications spanning pharmaceutical compositions (A61K), chemical compounds (C07D), and diagnostic methods (C12Q).
For intellectual property professionals and pharmaceutical companies, this publication establishes a priority date and public record of Repare Therapeutics' cancer treatment methodology. Companies developing similar targeted oncology therapies should review this application to assess potential freedom-to-operate implications or identify opportunities for licensing negotiations.
Archived snapshot
Apr 25, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
METHODS OF TREATING CANCERS HAVING A BIALLELIC LOSS OF FUNCTION OR GENE OVEREXPRESSION MUTATION
Publication EP4330426A1 Kind: A1 Apr 15, 2026
Applicants
Repare Therapeutics Inc.
Inventors
REIS, Jorge Sergio, KOEHLER, Maria, RIMKUNAS, Victoria, GLODZIK, Dominik, ZINDA, Michael, DABER, Robert, SILVERMAN, Ian
IPC Classifications
A61K 31/497 20060101AFI20250425BHEP A61K 31/519 20060101ALI20250425BHEP A61K 31/5377 20060101ALI20250425BHEP A61P 35/00 20060101ALI20250425BHEP C12Q 1/6809 20180101ALI20250425BHEP C07D 413/04 20060101ALI20250425BHEP C07D 471/04 20060101ALI20250425BHEP C07D 487/04 20060101ALI20250425BHEP C12Q 1/68 20180101ALI20250425BHEP C12Q 1/6886 20180101ALI20250425BHEP A61K 45/06 20060101ALI20250425BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Parties
Related changes
Get daily alerts for EPO Patent Bulletin - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Organic Chemistry (C07D) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.